Vancouver, British Columbia – August 4, 2011 – Sirona Biochem Corp. (TSX-V: SBM) (the “Company”), a biotechnology company specializing in carbohydrate chemistry technology, including the development of diabetes and obesity therapeutics, cosmeceuticals and biological ingredients, is pleased to announce its support of the Canadian Diabetes Association’s Proud Supporter Program in the amount of $25,000.
“As a company developing new treatments for diabetes, Sirona Biochem recognizes the importance of supporting ongoing research and education to improve the quality of life for those living with the disease,” said Sirona Biochem President Mark Senner.
“Companies like Sirona Biochem, who are passionate about helping people with diabetes live healthy lives, enable us to continue to provide valuable diabetes education and services in communities across Canada. We sincerely thank Sirona Biochem for supporting us in the fight against diabetes,” said Michael Cloutier, President and CEO of the Canadian Diabetes Association.”
Sirona Biochem’s Chief Executive Officer Dr. Howard Verrico and President Mark Senner presented a cheque to Canadian Diabetes Association representatives Connie Abram, Executive Director for Western Canada and Territories and Charlotte Lawson, Director of Fund Development.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company specializing in carbohydrate chemistry. We are applying a proprietary chemistry technique towards the development of diabetes therapeutics, cosmeceuticals and biological ingredients. Sirona Biochem aims to develop enhanced carbohydrate-based molecules by improving their pharmaceutical properties. Our lead product, a sodium glucose transporter (SGLT) inhibitor for Type 2 diabetes, recently achieved positive preclinical results. For more information visit www.sironabiochem.com.
About the Canadian Diabetes Association
Across the country, the Canadian Diabetes Association is leading the fight against diabetes by helping people with diabetes live healthy lives while we work to find a cure. Our community-based network of supporters help us provide education and services to people living with diabetes, advocate for our cause, break ground towards a cure and translate research into practical applications. Please visit diabetes.ca, join us on facebook.com/CanadianDiabetesAssociation, follow us on Twitter @DiabetesAssoc, or call 1-800-BANTING (226-8464). Visit diabetes.ca/proudsupporter to learn more about the Association’s Proud Supporter Program.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
-30-
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Regina Nebrida
Marketing and Communications Associate, Pacific
Canadian Diabetes Association
Phone: (604) 732-1331 ext.241
Email: regina.nebrida@diabetes.ca
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.